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OBJECTIVES We compared the accuracy of B-type natriuretic peptide (BNP) assay with Doppler
echocardiography for the diagnosis of decompensated congestive left-heart failure (CHF) in
patients with acute dyspnea.
BACKGROUND Both BNP and Doppler echocardiography have been described as relevant diagnostic tests for
heart failure.
METHODS One hundred sixty-three consecutive patients with severe dyspnea underwent BNP assay and
Doppler echocardiogram on admission. The accuracy of the two methods for etiologic
diagnosis was compared on the basis of the final diagnoses established by physicians who were
blinded to the BNP and Doppler findings.
RESULTS The final etiologic diagnosis was CHF in 115 patients. Twenty-four patients (15%) were
misdiagnosed at admission. The BNP concentration was 1,022  742 pg/ml in the CHF
subgroup and 187  158 pg/ml in the other patients (p  0.01). A BNP cutoff of 300 pg/ml
correctly classified 88% of the patients (odds ratio [OR] 85 [19 to 376], p  0.0001), but a
high negative predictive value (90%) was only obtained when the cutoff was lowered to 80
pg/ml. The etiologic value of BNP was low in patients with values between 80 and 300 pg/ml
(OR 1.85 [0.4 to 7.8], p  0.4) and also in patients who were studied very soon after onset
of acute dyspnea. Among the 138 patients with assessable Doppler findings, a “restrictive”
mitral inflow pattern had a diagnostic accuracy for CHF of 91% (OR 482 [77 to 3,011], p 
0.0001), regardless of the BNP level.
CONCLUSIONS Bedside BNP measurement and Doppler echocardiography are both useful for establishing
the cause of acute dyspnea. However, Doppler analysis of the mitral inflow pattern was more
accurate, particularly in patients with intermediate BNP levels or “flash” pulmonary
edema. (J Am Coll Cardiol 2002;40:1794–800) © 2002 by the American College of
Cardiology Foundation
Acute dyspnea is one of the main reasons for admission to
emergency departments. Rapid diagnosis of decompensa-
tion of congestive left-heart failure (CHF) is important for
prompt and appropriate treatment but is often difficult,
especially in elderly or obese subjects, and when associated
chronic pulmonary and cardiac diseases are present (1,2).
The B-type natriuretic peptide (BNP) has been described as
a powerful diagnostic test for heart failure (HF), even in the
emergency setting (3,4). Ultra-rapid assays are now available
and are suitable for bedside use (3–7). With the increasing
use of rapid BNP assays it is important to determine
diagnostic cutoff values. The BNP values increase with age
(8) but also during right ventricle overload (9,10); the latter
may be an important confounding factor, as the mean age of
patients hospitalized for HF is about 70 to 75 years and
chronic pulmonary disease is frequently associated (11).
Finally, BNP levels are highly sensitive to drugs used in the
treatment of HF (5). Bedside Doppler echocardiography is
now routinely used in many intensive care units to manage
patients with HF. It can be used to assess left ventricular
(LV) systolic function and offers an indirect estimate of LV
filling pressures (12,13). The value of bedside echocardiog-
raphy for the etiologic diagnosis of dyspnea has not been
adequately studied in the emergency setting.
We conducted a direct, prospective comparison of the
role of bedside BNP and Doppler echocardiography in
differentiating CHF from other causes in patients referred
to a cardiopulmonary intensive care ward because of severe
dyspnea.
METHODS
Study population. The study protocol was approved by the
local ethics committee. From June 1999 to June 2001, all
patients presenting to the emergency room of our institution
for acute severe dyspnea were enrolled, with the exception of
patients with acute myocardial infarction, chest injury, or
recent surgery. Among the 235 patients thus enrolled, 72
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patients were subsequently excluded because of treatments
(mechanical ventilation, diuretics, nitrates, or inotropic
agents) started more than 2 h before arrival in our depart-
ment, or because emergency echocardiography was not
feasible. Finally, 163 patients were included.
At inclusion, the cause of acute dyspnea was assessed by
the senior physician attending the patient on admission, on
the basis of a physical examination, electrocardiogram, and
chest X-ray examination.
Two groups served as controls. A cohort of 30 patients
age more than 65 years and hospitalized in the Medicine
Department, with no cardiac or pulmonary disease and no
history of hypertension or diabetes mellitus, served as a
control group for BNP values; Doppler echocardiogram was
performed in every case, and controls with any abnormality
were excluded. The second control group consisted of 30
outpatients with chronic stable HF (New York Heart
Association functional class II or III).
BNP assay. At inclusion, blood was immediately collected
in tubes containing potassium ethylenediamine-tetraacetic
acid (1 mg/ml blood) and plasma was stored at 80°C for
blinded BNP assay using the Triage B-Type Natriuretic
Peptide test (Biosite Diagnostics, San Diego, California), a
point-of-care method based on fluorescence immunoassay.
It is designed for quantitative determination of BNP in
whole blood and plasma, and it has been previously char-
acterized (6,14). Each sample was analyzed in duplicate (or
in triplicate when the first two values differed by more than
10%). The measurable range of BNP concentrations with
the Triage assay is 5 to 1,300 pg/ml. Samples were diluted
with normal plasma when values exceeded 1,300 pg/ml.
Bedside Doppler echocardiography. Doppler echocardio-
grams were obtained at the bedside within 60 min following
inclusion (30  9, 10 to 60 min), with a Hewlett-Packard
Sonos 1500 (Andover, Massachusetts) machine equipped
with a 2.5-MHz probe. The data were recorded on video-
tapes for later analysis by cardiologists experienced in
echocardiography. Echocardiographic examination and re-
cording took about 15 min and included two-dimensional
and M-mode examination, pulsed Doppler analysis of
mitral inflow, and continuous Doppler analysis of tricuspid
regurgitation. Pulsed Doppler analysis of mitral inflow
yielded three patterns: 1) an “impaired relaxation” pattern
(E/A ratio 1), suggesting no increase in LV filling
pressures; 2) a “restrictive” pattern (suggesting an increase in
LV filling pressures) when the E/A ratio was 2, or
between 1 and 2 with deceleration time of E-wave (DT)
130 ms, or DT130 ms alone in case of atrial fibrillation;
and 3) a “normal” or “normalized” pattern when the E/A
ratio was between 1 and 2 with the DT130 ms. Particular
care was taken to position the Doppler sample volume
between the mitral leaflet tips where flow velocity is highest.
When E and A waves were fused, slight sinocarotid massage
was used to reduce the heart rate and separate the two
waves. The mitral Doppler pattern was unavailable in 25
patients because of poor echogenicity, tachycardia, perma-
nent pacing, or mitral prosthesis. Systolic pulmonary arterial
pressure was calculated from the velocity of tricuspid regur-
gitation, when present. The left ventricular ejection fraction
(LVEF) was estimated mainly by visual inspection.
Final diagnoses. The final diagnosis was determined for
each patient by two cardiologists and one pneumologist,
who were blinded to the results of BNP assay and Doppler
echocardiography obtained on admission. All the patients’
medical records were reviewed. Confirmation of CHF was
based on the generally accepted Framingham criteria, with
corroborative information including the hospital course
(response to diuretics, vasodilators, inotropic agents, or
hemodynamic monitoring) and results of further cardiac
tests such as Doppler echocardiography, cardiac catheter-
ization, radionuclide ventriculography, and pulmonary
functional tests. Patients were finally classified as CHF or
non–CHF. This latter diagnosis included acute pulmonary
embolism and acute primary lung disorders, with or without
underlying LV dysfunction but with no evidence of CHF.
Statistical analysis. Categorical data are presented as num-
bers (percent), and continuous data as means  SD. The
Students t test and the Fisher exact test were used as
indicated. Group comparisons of BNP values were made
using analysis of variance (ANOVA) with the Newman-
Keuls post hoc test; p values  0.05 were considered
significant. Log-transformed BNP values were used in these
analyses to reduce the effects of the skewed distribution of
BNP concentrations. The sensitivity, specificity, accuracy,
and negative and positive predictive values of BNP assay
and Doppler echocardiography for CHF were compared.
We also computed receiver operating characteristic (ROC)
curves to determine optimal BNP cutoffs. We then used
stepwise multivariate logistic regression to determine
whether BNP assay and Doppler echocardiography added
independent diagnostic information to commonly collected
clinical variables. First, we developed a model based on
historical, physical, and radiological variables. Next, BNP
and Doppler findings were added separately to the model,
and improvements in the degree of fit were assessed using
the likelihood ratio test. The analyses were performed using
STATA 6.0 software for Windows (Stata Corporation,
College Station, Texas).
Abbreviations and Acronyms
ANOVA  analysis of variance
BNP  B-type natriuretic peptide
CHF  decompensated congestive left-heart failure
CI  confidence interval
DT  deceleration time of the mitral E-wave
HF  heart failure
LV  left ventricular
LVEF  left ventricular ejection fraction
OR  odds ratio
ROC  receiver operating characteristic
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RESULTS
The final diagnosis was CHF in 115 cases and non-CHF in
48 cases. Diagnosis of CHF was due to coronary artery
disease, hypertension, valve disease, and dilated cardiomy-
opathy in 49, 45, 20, and 42 cases, respectively. Non–CHF
was due to acute pulmonary embolism in 11 cases and
primary lung disorders in 37 cases (decompensated chronic
obstructive pulmonary disease or severe emphysema, pneu-
monia, pulmonary fibrosis, or severe asthma in 27, 5, 3, and
2 cases, respectively). The interval between the onset of
acute dyspnea and inclusion in the study ranged from 2 to
48 h (6 h in 18 patients). Acute dyspnea was generally
associated with severe clinical manifestations, as 90% of
patients were admitted to the intensive care unit and 21% of
these required mechanical ventilation. The main clinical
characteristics of patients are shown in Table 1, according to
the final diagnosis. The initial diagnosis was wrong in 24
patients (15%): CHF was wrongly diagnosed in 13 patients
and missed in 11 patients. In addition, 22 patients (13%)
had a “doubtful” initial diagnosis.
BNP and Doppler echocardiographic findings. Figure
1A shows box plots of log BNP values in each final
diagnostic group. Mean BNP concentrations were 1,022 
742 pg/ml in the acute CHF group, 187 158 pg/ml in the
non–CHF group, 44  39 pg/ml in the control group, and
144  142 pg/ml in the stable chronic HF group. The
intergroup difference was significant (p 0.001, ANOVA);
both the mean and the median were significantly higher in
the patients with CHF (p  0.001). No significant differ-
ence was observed between the other groups. Figure 1B
shows log BNP concentrations in various subgroups. The
BNP values in the non–CHF group were significantly
higher than in the control group without heart or lung
disease (p  0.05). As shown in Figure 1B, BNP concen-
trations were similar in patients with normal and abnormal
LVEF in the CHF group. In contrast, BNP values were
significantly higher when LVEF was abnormal in the
non–CHF group and also in patients with pulmonary
embolism (223  99 vs. 138  102 pg/ml and 294  245
vs. 155  106 pg/ml, respectively, p  0.05).
The main Doppler and echocardiographic findings are
Table 1. Clinical, ECG, and X-Ray Characteristics According
to Final Diagnosis
CHF
(n  115)
Non–CHF
(n  48) p Value
Age (yrs) 68.3  14.7 65.1  15.1 0.22
Gender (male/female) 80/35 29/19 0.28
History
Previous CHF (n, %) 72 (62.6%) 8 (16.7%)  0.001
Previous MI (n, %) 49 (42.6%) 4 (8.3%)  0.001
Hypertension (n, %) 45 (39.1%) 20 (41.7%) 0.86
Diabetes (n, %) 14 (12.2%) 9 (18.8%) 0.32
Signs
Orthopnea (n, %) 49 (42.6%) 7 (14.6%) 0.001
Rales (n, %) 87 (75.6%) 18 (37.5%)  0.001
Gallop (n, %) 19 (16.5%) 3 (6.25%) 0.13
Elevated JVP (n, %) 68 (59.1%) 10 (20.8%)  0.001
Pedal edema (n, %) 37 (32.2%) 7 (14.6%) 0.01
ECG and chest X-ray
Atrial fibrillation (n, %) 26 (22.6%) 5 (10.4%) 0.082
Heart enlargement (n, %) 81 (70.4%) 16 (33.3%)  0.001
X-ray edema (n, %) 100 (87.0%) 20 (41.67%)  0.001
CHF  decompensated congestive left-heart failure; ECG  electrocardiogram;
MI  myocardial infarction; JVP  jugular venous pressure.
Figure 1. Box plots showing median levels of B-type natriuretic peptide
(BNP) after logarithmic transformation. (A) Control groups (patients with
chronic stable heart failure (HF); and patients with no HF or lung disease)
and patients with acute dyspnea, according to the final diagnosis. *p 
0.001 between decompensated congestive left-heart failure (CHF) group
and others groups. **p  0.05 between non–HF group and “non–HF,
non–lung disease” group. (B) Various subgroups of CHF and non–CHF
patients, according to normal or abnormal left ventricular ejection fraction
(LVEF). **p  0.05.
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presented in Table 2. Systolic LV dysfunction, defined by an
LVEF of0.45, was found in 75 patients with CHF (65%)
and in 7 patients with other causes of dyspnea (14%). The
E/A ratio and the DT were significantly higher and lower,
respectively, in the patients with CHF. Finally, a “restric-
tive” mitral pattern was observed in 85 (89%) of the patients
with CHF and in only 3 (7%) of the patients with other
etiologic diagnoses. Systolic pulmonary artery pressures
were not significantly different among the various groups.
Etiologic diagnosis of acute dyspnea. None of the clini-
cal, electrocardiographic, or radiographic variables studied
had a diagnostic accuracy of more than 80% for CHF. Table
3 shows the sensitivity, specificity, positive and negative
predictive values, and accuracy of the most relevant BNP
cutoff values, LVEF values, and mitral Doppler patterns.
The most accurate BNP cutoff was 300 pg/ml (88% accu-
racy); this had a satisfactory positive predictive value (94%),
but a negative predictive value of only 75%. The best
negative predictive value (93%) was obtained with a BNP
cutoff of 80 pg/ml. Figure 2 shows the ROC curve illus-
trating these BNP cutoff values; the area under the ROC
curve was 0.93. Single LVEF values were poorly predictive
of the final diagnosis: using LVEF 0.45 as the criterion
for CHF, only 71% patients were correctly classified. The
best diagnostic performance was obtained with Doppler
analysis of mitral inflow: the “restrictive” pattern had an
accuracy of 91%. This result was similar whatever the
LVEF. Multivariate analysis demonstrated the independent
predictive value of five clinical and radiographic parameters
for CHF (Table 4). Both BNP and the Doppler mitral
pattern added significant incremental predictive diagnostic
value to the clinical variables, but BNP only predicted CHF
when levels were above 300 pg/ml (odds ratio [OR] 85, 95%
confidence interval [CI] [19.2 to 376.4], p  0.0001). The
“restrictive” mitral pattern was strongly predictive of CHF
(OR 481.7, 95%CI [77 to 3,011], p  0.0001).
Doppler echocardiography in patients with inconclusive
BNP values. Relevant negative and positive predictive
BNP values were scattered between 80 and 300 pg/ml,
respectively; within this range, BNP was poorly predictive of
the final diagnosis (OR 1.85, 95% CI [0.4 to 7.8], p  0.4)
(Table 4) and added nothing to the clinical diagnosis.
Among the 40 (25%) patients with such intermediate BNP
levels (Fig. 3), 12 were misdiagnosed by the attending
physician at admission, and only 6, 3, and 6 patients were
correctly identified by BNP cutoff values of 100, 200, and
300 pg/ml, respectively. In contrast, a “restrictive” Doppler
mitral pattern correctly classified 33 of these patients (4 had
Table 2. Doppler and Echocardiographic Findings According to
Final Diagnosis
CHF
(n  115)
Non–CHF
(n  48)
p
Value
Satisfying Doppler data (n, %) 95 (83%) 43 (90%)
LVEF 0.37  0.15 0.56  0.09  0.0001
LVEF 0.45 75 (65%) 7 (15%)  0.0001
E/A ratio 2.09  0.83 0.86  0.35  0.0001
DT (ms) 123.4  42.9 213.9  45.4  0.0001
“Restrictive” mitral pattern 85 (89%) 3 (7%)  0.0001
Systolic PAP (mm Hg) 50.4  20.4 46.5  12.0 0.25
CHF  decompensated congestive left-heart failure; DT  deceleration time of
E-wave; LVEF left ventricular ejection fraction; PAP pulmonary artery pressure.
Table 3. Value of Various BNP Cutoff Values, LVEF 0.45, and Doppler Mitral Pattern to
Diagnose Acute CHF
Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%)
Accuracy
(%)
BNP (pg/ml, n)
80 (15) 97 27 93 76 78
100 (18) 96 31 83 77 78
150 (29) 93 45 77 81 80
200 (35) 93 56 77 83 82
250 (44) 91 68 77 88 85
300 (55) 88 87 75 94 88
400 (70) 79 93 66 98 83
Doppler echocardiography (n)
LVEF  0.45 (82) 65 85 91 51 71
“Restrictive” mitral pattern (88) 89 93 80 96 91
BNP  B-type natriuretic peptide; CHF  decompensated congestive left-heart failure; LVEF  left ventricular ejection
fraction; NPV  negative predicative value; PPV  positive predictive value.
Figure 2. Receiver-operating characteristics curve for B-type natriuretic
peptide cutoff values. AUC  area under the curve.
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no assessable Doppler analysis of mitral inflow) and cor-
rected 10 of the 12 clinical misdiagnoses. The BNP assay
was also of limited value when blood was sampled very soon
after the onset of acute dyspnea. Among the 14 patients in
whom blood was sampled 4 h after onset, and who had a
final diagnosis of CHF, admission BNP levels were below
100 pg/ml in 4 patients and between 100 and 300 pg/ml in
6, whereas the Doppler mitral pattern was “restrictive” in 11
of these patients.
DISCUSSION
This is the first direct comparison of the etiologic value of
BNP assay and Doppler echocardiography in patients pre-
senting with acute dyspnea. Our results show that: 1) both
bedside BNP assay and Doppler echocardiography add
important diagnostic information to clinical findings in
emergency patients with acute dyspnea; and 2) the diagnos-
tic value of BNP is poor at levels between 80 and 300 pg/ml
and also in patients with “flash” pulmonary edema, whereas
the Doppler mitral inflow pattern is highly relevant.
Rapid etiologic diagnosis of acute dyspnea is often diffi-
cult (1), because of the nonspecific nature of signs (especially
in elderly and obese patients and subjects with a previous
history of cardiac or pulmonary disease), together with the
poor accuracy of electrocardiograms and chest radiography,
and frequent early and blind prescription of nitrates, diuret-
ics, aerosols, and antibiotics, often in combination. In our
study, 15% of patients were misdiagnosed at admission, a
rate close to that observed in another recent study of
emergency patients with dyspnea (4).
Natriuretic peptide concentrations are powerful biochem-
ical markers of HF (3,15) and they correlate well with
Table 4. Logistic Regression Analysis Using Significant Clinical Variables, BNP, and Doppler Mitral Pattern (n  138 Patients With
Adequate Doppler Analysis)
Model Included Variables OR (95% CI) p Value 2 of Model
Area Under ROC Curve
(95% CI)
1 Clinical characteristics 83.52 0.87 (0.82–0.93)
Previous MI 7.00 (1.9–26.2) 0.004
Orthopnea 4.05 (1.3–12.8) 0.017
Elevated JVP 3.53 (1.3–9.5) 0.013
X-ray edema 8.96 (3.0–26.5) 0.001
Previous CHF 5.10 (1.8–14.2) 0.002
2 BNP 94.47 0.93 (0.89–0.97)
80–300 pg/ml 5.38 (0.6–45.8) 0.12
300 pg/ml 221 (24.6–1983.1) 0.001
3 Doppler mitral pattern “restrictive” pattern 481.67 (77.0–3011.0) 0.001 111.95 0.95 (0.91–0.99)
4 Model 1  BNP* 129.03 0.96 (0.94–0.99)
5 Model 1  Doppler mitral pattern† 124.64 0.98 (0.96–0.99)
*Likelihood ratio test between model no. 4 and model no. 1: 2  45.5; p  0.001. †Likelihood ratio test between model no. 5 and model no. 1: 2  56.1; p  0.001.
BNP B-type natriuretic peptide; CHF decompensated congestive left-heart failure; CI confidence interval; JVP jugular venous pressure; MImyocardial infarction;
OR  odds ratio.
Figure 3. Diagnostic value of B-type natriuretic peptide (BNP) and Doppler mitral pattern for decompensated congestive left-heart failure (CHF) in 43
patients with BNP levels between 80 and 300 pg/ml.
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invasively measured LV filling pressures (16,17). Bedside
BNP assay has been facilitated by the advent of new rapid
tests such as the Triage kit used here. The results obtained
with these assays are close to those given by the time-
consuming radioimmunologic reference method (14). Dao
et al. (4) recently reported the good diagnostic value of a
rapid point-of-care BNP test in emergency patients present-
ing with dyspnea. They found that a BNP concentration of
80 pg/ml in whole blood had a negative predictive value of
98% and an accuracy of 95% for CHF, and they concluded
that BNP might be the test of choice for the differential
etiologic diagnosis of dyspnea. Nevertheless, Morrison et al.
(6) reported a wider dispersion of BNP levels in patients
with pulmonary diseases, and especially in patients with
acute pulmonary embolism.
Using the same assay, we confirm that BNP measurement
accurately discriminates between acute dyspnea due to CHF
and to other causes. However, while a BNP cutoff of 80
pg/ml had a strong negative predictive value (93%), accept-
able sensitivity and specificity, and a good positive predictive
value were only obtained with a cutoff of 300 pg/ml. The
diagnostic value of BNP fell at values between 80 and 300
pg/ml (i.e., in 26% of our patients). Many of these patients
had a final diagnosis of non–CHF; underlying LV dysfunc-
tion and/or severe pulmonary disease or pulmonary embo-
lism could explain the high BNP levels found in some
patients with acute dyspnea due to causes other than CHF.
Indeed, BNP concentrations can be elevated in patients
with compensated LV dysfunction or right ventricular
overload (9). This difference in cutoff values with previous
studies may be due to differences in the study populations.
Our population comprised patients with severe dyspnea
admitted to an intensive care unit, whereas a number of the
patients in the San Diego group study were not admitted
(4,6).
In contrast to our study, the final diagnoses of CHF in
these studies included not only LV HF but also pedal
edema, due to pulmonale cor, for example. Our study also
shows for the first time that low BNP values can be observed
in patients with CHF, especially those with “flash” pulmo-
nary edema and when blood is assayed very soon after the
onset of dyspnea. These “false-negative” results may be
explained by the lag-time between acute LV overload and
BNP secretion into the circulation (18), and also by the
absence of LV systolic dysfunction.
Doppler echocardiography, and especially Doppler anal-
ysis of the mitral inflow pattern, was highly accurate in
distinguishing between acute dyspnea due to CHF and
forms due to other causes. To our knowledge, ours is the
first study to show such diagnostic value in the emergency
setting. Several studies have shown strong correlations of
the E/A ratio, DT, and the mitral inflow pattern with LV
end diastolic pressure and pulmonary capillary wedge pres-
sure at rest (12,13). However, these relationships were
mainly observed in patients with LV systolic dysfunction. In
our study, Doppler analysis of the mitral inflow pattern
remained relevant in patients with a preserved LVEF,
possibly because of the patients’ advanced age, the acute
setting, and the use of simple criteria (“restrictive” vs.
“nonrestrictive” patterns). More refined Doppler analysis
can be obtained with pulsed Doppler analysis of pulmonary
venous flow, color M-mode analysis of LV inflow, and
Doppler tissue imaging of the mitral annulus (19,20).
However, these measurements are time-consuming and
require a well-trained operator, making them poorly suited
to the emergency setting and dyspneic patients: in contrast
to Doppler analysis of the mitral inflow pattern, pulmonary
venous flow was only assessable in about 25% of our patients
(data not shown). It should be noted that our Doppler
studies were performed in severely dyspneic patients in
whom treatment had been started 2 h previously. Subse-
quent identical Doppler examination at the echo lab, after
diuretic and vasodilator therapy, and clinical improvement,
often showed markedly different findings with, for example,
an E/A ratio 1 in most of the patients with a preserved
LVEF, as well as in elderly patients without CHF. Finally,
only four patients with CHF had an E/A ratio 1 at
admission; this could be explained by abrupt changes in load
during aggressive initiation of treatment or by marked,
isolated impairment of relaxation (21).
The relatively poor diagnostic value of the LVEF com-
pared to Doppler mitral analysis is not surprising: CHF and
pulmonary edema are often found in patients (who are
frequently old) with a preserved LVEF (22); this was the
case in 35% of our patients. Finally, echocardiographic
machines usually have limited availability in the emergency
care setting, but the emergence of portable ultrasound
imagers (23), including Doppler devices, could permit their
more widespread use.
Figure 4. Algorithm for the etiologic diagnosis of acute dyspnea, based on
B-type natriuretic peptide (BNP) assay and Doppler echocardiography.
CHF  decompensated congestive left-heart failure; ECG  electrocar-
diogram.
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Study limitations. This study included patients with par-
ticularly severe dyspnea; whether or not our results can be
extrapolated to patients with milder dyspnea remains to be
shown. In addition, CHF was the most frequent final
diagnosis, and patients with non–CHF diagnoses had severe
lung disease, with probably frequent chronic and/or acute
pulmonale cor. This could partly explain the relatively high
optimal BNP cutoff of 300 pg/ml obtained here, as the
prevalence of right ventricular or LV failure was lower in
other studies. Finally, the high diagnostic value of Doppler
echocardiography found here may be markedly decreased if
the examination is performed later after arrival or initiation
of treatment.
Clinical implications. This study suggests that both BNP
assay and Doppler echocardiography can be used for the
diagnosis of CHF in acutely dyspneic patients. Bedside
BNP assay is simple and repeatable. Doppler analysis of
mitral inflow is at least as effective as BNP assay in this
setting, but was not feasible in 15% of our patients. We
propose a diagnostic algorithm (Fig. 4), in which bedside
BNP assay is first used to rule out CHF (values 80 pg/ml)
or to confirm CHF (values 300 pg/ml). In patients with
“intermediate” BNP levels (i.e., between 80 and 300 pg/ml),
Doppler echocardiography is used to confirm or rule out
CHF.
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